A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk (Q34500117)

2 August 2017

A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk (English)

1 reference

2 August 2017

4

Xiaoxin Meng

1 reference

2 August 2017

6

Hongzhou Cai

1 reference

2 August 2017

Qiang Cao

1

1 reference

2 August 2017

Xiaobing Ju

2

1 reference

2 August 2017

Pu Li

3

1 reference

2 August 2017

Pengfei Shao

5

1 reference

2 August 2017

Meilin Wang

7

1 reference

2 August 2017

Zhengdong Zhang

8

1 reference

2 August 2017

Chao Qin

9

1 reference

2 August 2017

Changjun Yin

10

1 reference

2 August 2017

language of work or name

English

0 references

publication date

28 November 2012

1 reference

2 August 2017

1 reference

2 August 2017

7

1 reference

2 August 2017

e50302

1 reference

2 August 2017

11

1 reference

Creative Commons Attribution 4.0 International

2 August 2017

start time

28 November 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

A functional polymorphism C-1310G in the promoter region of Ku70/XRCC6 is associated with risk of renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

The epidemiology of renal cell carcinoma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Epidemiology and risk factors for kidney cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

VHL and HIF signalling in renal cell carcinogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

PI3K/PTEN signaling in angiogenesis and tumorigenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Perturbations of the AKT signaling pathway in human cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Cell signaling by receptor tyrosine kinases

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

7 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

Mammalian target of rapamycin expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050302

Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508984

Chromosome 11q13.3 variant modifies renal cell cancer risk in a Chinese population

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23209702

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23209702

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23209702

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0050302

1 reference

2 August 2017

0 references

1 reference

2 August 2017

1 reference